Therapeutic Efficacy, Safety and Predictive Indicators of Eribulin Plus Anti-Angiogenic Medicine for Metastatic Breast Cancer

Therapeutic Efficacy, Safety and Predictive Indicators of Eribulin Plus Anti-Angiogenic Medicine for Metastatic Breast Cancer. (2024). Journal of the College of Physicians and Surgeons Pakistan, 34(06), 682–687. https://doi.org/10.29271/jcpsp.2024.06.682
Authors:
Junmei Zhang
Xuezheng Wang
Hongjuan Du
Yan Xue
Affiliated Authors:
Xuezheng Wang
Columbia Affiliation:
Subjects:
Furans (MeSH)
Ketones (MeSH)
Breast Neoplasms (MeSH)
Angiogenesis Inhibitors (MeSH)
Antineoplastic Combined Chemotherapy Protocols (MeSH)
Chemotherapy-Induced Peripheral Neuropathy in Cancer Treatment (OpenAlex Topic)
Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer (OpenAlex Topic)
HER2 Signaling in Breast Cancer Treatment (OpenAlex Topic)
Author Keywords:
anti-angiogenic therapy
eribulin
metastatic breast cancer
predictive indicators of efficacy
elink
Publication Type:
Article
Unique ID:
10.29271/jcpsp.2024.06.682
PMID:
38840351
DOI:
10.29271/jcpsp.2024.06.682
Journal:
JCPSP
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: